<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556800</url>
  </required_header>
  <id_info>
    <org_study_id>VML-0203-002</org_study_id>
    <nct_id>NCT03556800</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Pharmacokinetics &amp; Safety Following One Application of 3 Different Doses 0.5,0.75,&amp; 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.</brief_title>
  <official_title>A Phase I, Randomized, Open-Label, Single Center, Cross-over Study to Investigate the Pharmacokinetics and Safety Following a Single Application of Three Different Doses 0.5 gm (0.5 mg Estradiol), 0.75 gm (0.75 mg Estradiol) and 1.25 gm (1.25 mg Estradiol), a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGelTM 1.25 gm (1 Unit/0.75 mg of Estradiol) to Healthy Post-menopausal Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viramal Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Viramal Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase I, Randomized, Open-Label, Single Center, Cross-over Study to
      Investigate the Pharmacokinetics and Safety following a Single Application of Three Different
      Doses 0.5 gm (0.5 mg estradiol), 0.75 gm (0.75 mg estradiol) and 1.25 gm (1.25 mg estradiol),
      a Transdermal Estradiol Cream (VML-0203), in comparison to a single dose of EstroGelTM 1.25
      gm (1 unit/0.75 mg of estradiol) to healthy post-menopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the bio-availability of estradiol and estrone.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Blood samples will be analysed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide general safety information for VML-0203.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Application site inspections will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>0.5 gm of EstroCream (VML-0203)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75 gm of EstroCream (VML-0203)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.25 gm of EstroCream (VML-0203)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.25 EstroGel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogel</intervention_name>
    <description>Each subject will receive the following IMPs in accordance with the randomisation code:
Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream
Reference IMP: a single-dose of 1.25g EstroGel</description>
    <arm_group_label>0.5 gm of EstroCream (VML-0203)</arm_group_label>
    <arm_group_label>0.75 gm of EstroCream (VML-0203)</arm_group_label>
    <arm_group_label>1.25 EstroGel</arm_group_label>
    <arm_group_label>1.25 gm of EstroCream (VML-0203)</arm_group_label>
    <other_name>EstroCream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be a healthy post-menopausal (surgical or natural) female.

          -  Serum estradiol levels between 0-20 pg/ml.

          -  FSH levels greater than 25.8 mIU/ml.

          -  Greater than 45 years of age if surgical menopausal &gt; 30 yrs. of age.

          -  Have a body mass index (BMI) between 20 and 30 kg/m2.

          -  Have had a normal PAP smear test result within the last year before the study entry.

        Exclusion Criteria:

          -  Is pregnant (urine pregnancy test at screening) or lactating.

          -  Has evidence of drug or alcohol abuse.

          -  Have used hormonal replacement or vaginal hormonal therapy within the past three
             months before study entry.

          -  Have used estrogen pellet therapy or progestin injectable drug therapy within the past
             three months before study entry.

          -  Has contraindications to HRT use, including: unexplained vaginal bleeding, liver
             disease, breast or endometrial cancer, venous thromboembolic events.

          -  Any subjects with an obvious presence of skin conditions, excessive hair at the
             application sites (no shaving), scar tissue, tattoo, or coloration that would
             interfere with application of IMP, skin assessment, or reactions to drug.

          -  Presence of open sores at the application sites.

          -  Any subjects with a history of significant skin disorder.

          -  Smoker.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Finn Larsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Finn Larsen, MD</last_name>
    <phone>020 7495 3052</phone>
    <email>flarsen@viramal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Simbec Research Ltd</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Wales</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Galligan</last_name>
      <phone>+44 (0)1443 694334</phone>
      <email>laura.galligan@simbec.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoestrogenism</keyword>
  <keyword>Menopausal hormone therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

